Skip to main content

Table 6 Responder rates (%) according to weekly incontinence episodes by cause of FI (ITT)

From: Skeletal muscle-derived cell implantation for the treatment of sphincter-related faecal incontinence

  Muscle damage (N = 16) Atrophy (N = 17) Both (N = 6)
V2 V3 V4 V2 V3 V4 V2 V3 V4
R(0–19) 25.0 12.5 12.5 5.9 11.8 11.8 16.7 0.0 0.0
R(20–49) 31.3 18.8 25.0 29.4 11.8 0.0 66.7 33.3 0.0
R(50–99) 43.8 56.3 50.0 52.9 58.8 70.6 16.7 66.7 83.3
R(100) 0.0 12.5 12.5 11.8 17.6 17.6 0.0 0.0 16.7
  1. FI faecal incontinence, ITT intention to treat, N number of values, V visit, V2, V3 and V4 1, 6 and 12 months post implantation, R(0–19), R(20–49), R(50–99) and R(100) percentage of patients with decrease in weekly incontinence episodes of 0–19%, 20–49%, 50–99%, and 100%, respectively from baseline (V0) to post-implantation visits